Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
CXCL6 antibody neutralization prevents lung inflammation and fibrosis in mice in the bleomycin model
Journal of Leukocyte Biology, Volume 94, No. 6, Year 2013
Notification
URL copied to clipboard!
Description
IPF is a chronic, progressive pulmonary disease, leading to respiratory failure. In search of mechanisms of IPF, we used the bleomycin-induced lung-injury model in mice, which causes acute inflammation that may progress to chronic lung inflammation and fibrosis. Here, we asked whether CXCL6/GCP-2, a member of the CXC chemokine superfamily, may be involved in IPF development. First, we reported an increase of CXCL6 levels in BALF from patients with IPF, as well as in the lung of mice, 24 h after bleomycin administration. To investigate whether CXCL6 played a role in experimental bleomycin-induced pulmonary fibrosis, we treated mice with an anti-mCXCL6 mAb that has been shown to inhibit neutrophil chemotaxis in vitro. CXCL6 antibody blockade attenuated acute inflammation with a reduced pulmonary neutrophil influx, IL-1Β, CXCL1, and TIMP-1 production. In the later phase (14 days after bleomycin exposure), lymphocyte recruitment and fibrosis markers, such as collagen and TIMP-1, were diminished, as well as collagen deposition and fibrotic lesion the lung. Therefore, the data suggest that CXCL6 contributes to experimental pulmonary fibrosis, and CXCL6 inhibition might be used to reduce lung toxicity associated with bleomycin treatment. J. Leukoc. Biol. 94: 1317-1323; 2013. © Society for Leukocyte Biology.
Authors & Co-Authors
Besnard, Anne Gaëlle
France, Paris
Cnrs Centre National de la Recherche Scientifique
South Africa, Cape Town
University of Cape Town
Struyf, Sofie
United Kingdom, Glasgow
University of Glasgow
Guabiraba, Rodrigo
South Africa, Cape Town
University of Cape Town
Fauconnier, Louis
France, Orleans
Artimmune
Rouxel, Nathalie
France, Orleans
Artimmune
Proost, Paul
United Kingdom, Glasgow
University of Glasgow
Uyttenhove, Catherine
Belgium, Leuven
Rega Institute for Medical Research
van Snick, Jacques L.
Belgium, Leuven
Rega Institute for Medical Research
Couillin, Isabelle
France, Paris
Cnrs Centre National de la Recherche Scientifique
Ryffel, Bernhard
France, Paris
Cnrs Centre National de la Recherche Scientifique
France, Orleans
Artimmune
Belgium, Louvain-la-neuve
Université Catholique de Louvain
Statistics
Citations: 10
Authors: 10
Affiliations: 6
Identifiers
Doi:
10.1189/jlb.0313140
e-ISSN:
19383673
Research Areas
Violence And Injury